Description
Data Bridge Market Research analyses that The Hidradenitis Suppurativa Market was valued at USD 696.58 million in 2021 and is expected to reach USD 1,005.88 million by 2029, registering a CAGR of 4.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Hidradenitis suppurativa (HS), commonly known as acne inversa, is a chronic inflammatory skin illness that affects the axillae, groin, and under the breasts. It's marked by recurrent or persistent boil-like nodules and abscesses, which lead to a purulent flow, sinusitis, and scarring. HS can have a substantial psychological impact, and many patients experience anxiety, despair, and body image issues as a result.
Market Analysis and Size
In recent years, the hidradenitis suppurativa market is anticipated to grow rapidly during the forecast period. Hidradenitis suppurativa, often known as acne inversa, is a chronic dermatological condition characterized by swollen lumps. Hormonal imbalances, friction from clothing, and sweating cause hidradenitis suppurativa. According to a 2014 article published in Current Dermatology Reports, the condition is also caused by smoking, obesity, and genetic factors. Hence, the demand for hidradenitis suppurativa market is increased.
Report Scope and Market Segmentation
· Segments Covered: Clinical Stage (Hurley Stage 1, Hurley Stage 2, Hurley Stage 3), Skin Condition (Folliculitis, Pimples, Boils, Deep-Acne, Others), Treatment Type (Surgery, Medications, Photodynamic Therapy (PDT), Laser Treatment, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
Countries Covered:
· U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered:
· Bayer AG (Germany), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Eli Lilly and Company (US), AbbVie Inc. (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.( Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Allergan (Ireland), Merck & Co., Inc. (US), Zydus Cadila (India), Eisai Co., Ltd. (Japan)
Market Opportunities:
- Increase in the number of emerging markets
- Increase in the number of research and development activities
- Technological advancement
- Surging drug approvals and launches
Hidradenitis Suppurativa Market Scope
The hidradenitis suppurativa market is segmented on the basis of clinical stage, skin condition, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Clinical Stage
· Hurley Stage 1
· Hurley Stage 2
· Hurley Stage 3
Skin Condition
· Folliculitis
· Pimples
· Boils
· Deep-Acne
· Others
Treatment Type
· Surgery
· Medications
· Biologics
· Antibiotics
· Hormonal Therapy
· Immunosuppressive Drugs
· Zinc Supplements
· Retinoids
· Pain Medication
· Others
· Photodynamic Therapy (PDT)
· Laser Treatment
· Others
Route of Administration
· Oral
· Parenteral
· Others
End-Users
· Hospitals
· Specialty Clinics
· Homecare
· Others
Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
· Online Pharmacy
· Others
Hidradenitis Suppurativa Market Regional Analysis/Insights
he Hidradenitis suppurativa market is analysed and market size insights and trends are provided by country, clinical stage, skin condition, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Hidradenitis suppurativa market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.North America dominates the hidradenitis suppurativa market because of the surging adoption of newer techniques in this region. Additionally, growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate in this region.
Major TOC of the Nephrology and Urology Devices Market Report
Chapter One:
· MARKET SEGEMENTATION
· EXECUTIVE SUMMARY
· PREMIUM INSIGHTS
· MARKET OVERVIEW
Get TOC of the Report: https://www.databridgemarketresearch.com/toc/?dbmr= -hidradenitis-suppurativa-market
Competitive Landscape and Hidradenitis Suppurativa Market Share Analysis
The Hidradenitis suppurativa market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hidradenitis suppurativa market.
Some of the major players operating in the hidradenitis suppurativa market are:
· Zydus Cadila (India)
· Eli Lilly and Company (US)
· Sun Pharmaceutical Industries Ltd. (India)
· Aurobindo Pharma (India)
· Lupin (India)
· Mylan N.V. (US)
· Teva Pharmaceutical Industries Ltd. (Israel)
· Johnson & Johnson Private Limited (US)
· AstraZeneca (UK)
· Merck & Co., Inc. (US)
· Bayer AG (Germany)
· AbbVie Inc. (US)
· Abbott (US)
· F. Hoffmann-La Roche Ltd. (Switzerland)
· Sanofi (France)
· Novartis AG (Switzerland)
· Aurobindo Pharma (India)
· Lupin (India)
· Pfizer Inc. (US)
·
